Earnings Report | 2026-04-18 | Quality Score: 95/100
Earnings Highlights
EPS Actual
$-0.43
EPS Estimate
$-1.6279
Revenue Actual
$None
Revenue Estimate
***
Real-time US stock gap analysis and overnight movement tracking to understand pre-market and after-hours trading activity. We provide comprehensive extended-hours coverage that helps you anticipate opening price action.
Calidi Biotherapeutics Inc. (CLDI) recently released its the previous quarter earnings results, reporting no revenue for the quarter and a GAAP earnings per share (EPS) of -$0.43. As a clinical-stage biotechnology company focused on developing novel allogeneic immunotherapies for hard-to-treat cancers, the absence of revenue in the period is aligned with its current pre-commercial operating status, as it has not yet brought any therapeutic candidates to market or finalized revenue-generating col
Executive Summary
Calidi Biotherapeutics Inc. (CLDI) recently released its the previous quarter earnings results, reporting no revenue for the quarter and a GAAP earnings per share (EPS) of -$0.43. As a clinical-stage biotechnology company focused on developing novel allogeneic immunotherapies for hard-to-treat cancers, the absence of revenue in the period is aligned with its current pre-commercial operating status, as it has not yet brought any therapeutic candidates to market or finalized revenue-generating col
Management Commentary
During the official the previous quarter earnings call, Calidi Biotherapeutics leadership framed the quarterly results as a reflection of the company’s strategic priority to advance its pipeline of stem cell-based oncology therapies through critical pre-clinical and early clinical milestones. Management noted that the majority of quarterly expenditures were allocated to pre-clinical testing of its lead candidate, manufacturing process optimization to support future clinical trial supply, and hiring specialized clinical operations staff to oversee upcoming trial enrollment. Leadership also emphasized that the lack of revenue in the previous quarter was expected for the firm’s current development stage, and that the company’s current capital reserves are sufficient to support planned R&D activities for the foreseeable future. No unannounced pipeline setbacks or unexpected operational costs were disclosed during the public portion of the call, and leadership reiterated its commitment to keeping operational burn rates within previously disclosed projected ranges.
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Real-time data enables better timing for trades. Whether entering or exiting a position, having immediate information can reduce slippage and improve overall performance.Some traders prefer automated insights, while others rely on manual analysis. Both approaches have their advantages.CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Combining qualitative news with quantitative metrics often improves overall decision quality. Market sentiment, regulatory changes, and global events all influence outcomes.
Forward Guidance
CLDI did not provide specific quantitative revenue guidance for upcoming periods, consistent with standard practice for pre-commercial biotech firms with no near-term commercial launch plans. Management noted that near-term operational milestones may include submission of investigational new drug (IND) applications to regulatory bodies for lead candidates, release of additional pre-clinical efficacy and safety data, and initiation of Phase 1 clinical trial enrollment for its most advanced program. Leadership also noted that operating expenses would likely remain elevated in the coming months as the company scales its R&D and clinical operations, which could result in continued net losses per share until the firm secures partnership revenue, licensing agreements, or successfully launches a commercial product. No specific timelines for regulatory submissions or trial initiation were provided in the public earnings materials, with management noting that timelines may shift based on regulatory feedback and pre-clinical testing results.
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Monitoring macroeconomic indicators alongside asset performance is essential. Interest rates, employment data, and GDP growth often influence investor sentiment and sector-specific trends.Correlating futures data with spot market activity provides early signals for potential price movements. Futures markets often incorporate forward-looking expectations, offering actionable insights for equities, commodities, and indices. Experts monitor these signals closely to identify profitable entry points.CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Cross-market observations reveal hidden opportunities and correlations. Awareness of global trends enhances portfolio resilience.
Market Reaction
Based on available market data, trading activity in CLDI in the sessions following the the previous quarter earnings release was in line with average recent trading volumes, with no unusual price volatility observed immediately after the announcement. Analysts covering the biotech sector note that the reported the previous quarter results were largely aligned with broad market expectations for pre-commercial oncology biotechs of similar size and pipeline stage, with the reported EPS figure matching consensus analyst estimates published ahead of the release. Analyst notes following the earnings call highlight that future performance of Calidi Biotherapeutics may be primarily driven by pipeline progress and regulatory milestones rather than near-term financial results, given the absence of commercial products. Investor sentiment around CLDI could shift based on upcoming pipeline announcements, with potential positive momentum from successful pre-clinical data releases or regulatory approvals to advance trials, or possible downward pressure if development timelines are extended beyond current market projections.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Some investors find that using dashboards with aggregated market data helps streamline analysis. Instead of jumping between platforms, they can view multiple asset classes in one interface. This not only saves time but also highlights correlations that might otherwise go unnoticed.Monitoring macroeconomic indicators alongside asset performance is essential. Interest rates, employment data, and GDP growth often influence investor sentiment and sector-specific trends.CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Some traders combine sentiment analysis with quantitative models. While unconventional, this approach can uncover market nuances that raw data misses.
